Chelate Compounds

Modified manganese(II) chelates with hydroxyalkyl and aryl substitutions address the instability issue of existing compounds, providing enhanced stability and effectiveness as MRI contrast agents.

JP7594560B2Active Publication Date: 2024-12-04GE HEALTHCARE AS
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2022049034
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-06-20
Filing Date
2022-03-24
Publication Date
2024-12-04
Estimated Expiration
2037-06-20

AI Technical Summary

Technical Problem

Existing paramagnetic chelate compounds used in MRI, particularly those based on manganese(II), suffer from instability and rapid dissociation in vivo, leading to potential toxicity and reduced effectiveness as contrast agents.

Method used

Development of manganese(II)-based chelates with specific structural modifications, including hydroxyalkyl and aryl substitutions, to enhance kinetic inertness and stability, ensuring slow dissociation and improved relaxivity.

Benefits of technology

The modified manganese(II) chelates exhibit enhanced in vivo stability, maintaining effective contrast agent properties and reducing the risk of toxicity, making them suitable for improved MRI applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594560000110
    Figure 0007594560000110
  • Figure 0007594560000111
    Figure 0007594560000111
  • Figure 0007594560000112
    Figure 0007594560000112
Patent Text Reader

Abstract

Chelate compounds suitable for use as contrast agents in magnetic resonance imaging (MRI) are provided. The present invention provides manganese chelate compounds that maintain relaxivity properties and have improved kinetic stability.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to chelating compounds and their use as contrast agents in magnetic resonance imaging (MRI) procedures. Concerning its use. [Background technology]

[0002] MRI is a medical imaging technique that visualizes areas of the body with the nuclei of selected atoms, specifically hydrogen nuclei. The MRI signal is generated by the environment surrounding the visualized nuclei and by the longitudinal and transverse relaxation times. The time depends on T1 and T2. Therefore, if the visualized nuclei are protons, However, MRI signal intensity depends on factors such as proton density and the chemical environment of the protons. Contrast agents can be used in MRI to improve image contrast. They are T1, T2 and / or T2 * This creates a relaxation time, which in turn changes the image control. It works by affecting the last.

[0003] T1, T2 and / or T2 * The relaxation time is It is known that the paramagnetic ions can be optimized for use as contrast agents. The presence and residence time of water molecules bound to the paramagnetic agent and the rotational correlation time of the contrast agent. The presence and residence time of water molecules bound to the ion are determined by the selection of paramagnetic ions and chelating moieties. The rotational correlation time can be adjusted by changing the size of the contrast agent. It can be adjusted.

[0004] Several types of contrast agents are known for use in MRI. Blood pool MR contrast agents, e.g. For example, superparamagnetic iron oxide particles are retained in the vasculature for long periods of time. However, it is extremely useful for enhancing contrast in tumors, which is a result of tumor vascularization. It is also extremely useful for detecting capillary permeability abnormalities, such as "leaky" capillary walls in tumors. It was shown that.

[0005] Because paramagnetic chelates are administered to patients in relatively large doses, they are used as contrast agents for MRI. When paramagnetic chelates are used, the solubility of the chelate in water is also an important factor. Since the amount of active chelate required is small, it is easier to administer to the patient and causes less discomfort. Water-soluble paramagnetic chelates, i.e., complexes of chelating agents with paramagnetic metal ions, are well known. For example, the commercially available gadolinium chelate Omniscan™ (GE Healthcare); Dotarem(TM) (Guerbet), Gadavist(TM) (Bayer) and and Magnevist™ (Bayer). They have a low molecular weight and therefore are difficult to penetrate into the vasculature. Upon administration, they are rapidly distributed into the extracellular space (i.e., blood and interstitium). , they are eliminated from the body relatively quickly.

[0006] Several publications have described the research carried out with the aim of developing improved paramagnetic chelating compounds. For example, U.S. Patent No. 8,540,966 describes the following generalized structure: Teach:

[0007] [ka] In the above formula, L is a linker and R is H or C 2~70 It is an aminopolyol moiety. The experimental examples in U.S. Pat. No. 8,540,966 show the synthesis of some of these compounds and commercially available gadolinium. Compared to mucilagene, it shows a similar pharmacokinetic profile but with greater mildness .

[0008] EP 1931673 teaches the following generalized structure:

[0009] [ka] Each R in the above structure is defined as a coordinating ligand in EP 1931673. , each X has at least one C 1~6 Contains hydroxyalkyl groups. European Patent No. 1931 EP 1931673 emphasizes the relaxivity properties of the compound. , Gd 3+ , Mn 2+ and Fe 3+ and complexed with a paramagnetic metal ion selected from However, the focus is on Gd 3+ A chelate structure suitable for stable complexation of For example, in the following gadolinium-containing complex:

[0010] [ka] All disclosed complexes are heptadentate, with gold complexed to four nitrogens and three carboxylate groups. The adverse effects of heptadentate manganese chelates are discussed in WO 201107 It is described in No. 3371.

[0011] An important property of MRI chelates is that the paramagnetic ion is retained within the chelate structure as long as possible. The paramagnetic ions released from the chelates in vivo can then be transported through biological pathways. The ability of the chelate to retain paramagnetic ions (see herein) can interfere with the The stability of the cheland part is determined by the structural design. Of particular interest is the dissociation half-life, which is measured by the The kinetic stability of a molecule is its ability to withstand altered chemical environments (i.e., endogenous ions). The above publications show the degree of inertia of the compounds described therein. (transmetallation inertness) is not considered.

[0012] As can be seen from the commercial drugs and prior art focus, gadolinium is an MRI It is the most widely used paramagnetic metal ion for rate, due to its favorable relaxation properties The stability of the cation in the chelate structure is dependent on the amount of free gadolinium and its toxicity. This is of particular importance to gadolinium chelates because of the well-known problems associated with them. These problems Therefore, there is an incentive to seek alternatives to gadolinium.

[0013] The manganese(II) ion is a paramagnetic species with a high spin number and long electronic relaxation time. The potential of manganese(II)-based high relaxivity contrast agents has been reported in the literature (Toth, E;Advances in Inorganic Chemistry,2009,6 1(09), 63-129). However, the specific manganese(II) oxides developed to date have not been It was found that the chelates were less stable compared to the corresponding gadolinium chelates. For example, the manganese chelate of DOTA (MnDOTA) is It is several hundred times more unstable than GdDOTA(Drahos, B; Inorganic Chemistry,2012(12),1975-1986).

[0014] The work described in WO 2011073371 demonstrated high chelate stability and This shows that these compounds have a molecular design that favors low relaxivity. The exemplary compounds of WO2011073371 are It has the following structure (also referred to herein as the "prior art Mn chelate"):

[0015] [ka] Nevertheless, improved and sustained dynamics while maintaining viable relaxation properties There is still room for additional manganese chelates with structural stability. [Prior art documents] [Patent documents]

[0016] [Patent Document 1] International Publication No. 2011 / 073371 Summary of the Invention

[0017] In one aspect, the present invention provides a compound of formula I:

[0018] [ka] or a salt or solvate thereof, Each R 1 are independently 1~20 Hydroxyalkyl, C 1~6 Alkyl, halo and -C(=O)-NH-C 1~6 one or more substituents selected from hydroxyalkyl C optionally substituted with a group 3~6 aryl, or carbohydrate moiety. ; Each R 2 are independently1~20 Hydroxyalkyl, C 1~6 Alkyl or Hydrogen Selected from the group comprising: R 3 is C 1~3 Alkyl, or -(CH2) where m is an integer from 2 to 5 m -C(=O )-NR 5 R 6 and R 5 and R 6 is R 1 and R 2 About it as defined in each of the following: R 4 is hydroxy, C 1~6 Alkyl and C 1~6 From the group containing hydroxyalkyl represents 0 to 3 substituents selected from the following; and Each n is an integer from 0 to 4; Additionally, the compounds of formula I contain at least two hydroxy groups.

[0019] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: (i) activating the carboxylate group of a compound of formula II with a peptide reagent

[0020] [ka] (II) ;next, (ii) reacting the activated compound of formula II with a substituent -NR 1 R 2 The amine derivatives and Combined, R 1 and R 2 The process for arriving at the compound of formula I, The present invention provides a process for the preparation of a compound of formula I of the present invention, comprising the steps of:

[0021] In a further aspect, the present invention provides a compound of formula III

[0022] [ka] wherein X1 is methyl or -(CH2)3-COOH, Processes are provided for the preparation of compounds of formula II as defined herein.

[0023] In a further aspect, the present invention provides a compound of formula I of the present invention administered to a mammal in combination with a biocompatible carrier. The present invention provides pharmaceutical compositions containing the compound in a form suitable for administration.

[0024] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: (i) administering a compound of formula I of the invention or a pharmaceutical composition of the invention to a subject; (ii) detecting magnetic resonance (M R) Signal detection; (iii) generating MR images and / or MR spectra from the detected signals; The present invention provides a method comprising:

[0025] The compounds of the invention have been shown to have properties indicative of their utility as MRI contrast agents. Ta.

[0026] The solubility of the compounds of the invention, measured as described in Example 13, is useful for imaging in MRI. Their suitability for use as agents has been demonstrated.

[0027] In Vitro Relaxivity Measurements to Evaluate the Efficacy of Compounds of the Invention (See Example 14) These compounds are known to increase both the longitudinal and transverse relaxation rates of water molecules coordinated to metal ions (e.g. It was shown that it induces an increase in 1 / T1 and 1 / T2, respectively.

[0028] Experiments to test the kinetic inactivity of the compounds of the present invention were carried out using competing gold ions in a weakly acidic solution. Group ion Cu 2+and Zn 2+ (See Example 15.) These experiments have shown that the compounds of the present invention have favourable characteristics compared to the prior art.

[0029] The compounds of the present invention have a slow dissociation rate compared to the compounds of the prior art, namely Mn(II)-based chelates. showed improved kinetic inactivity of

[0030] So, in summary, the compounds of the present invention provide heretofore undocumented Mn(II) The chelating compounds provide a favorable balance between contrast agent efficiency and improved stability in vivo. The additional in vivo stability makes the compounds of the present invention suitable for the next generation of clinical imaging agents for medical MRI. We show that this could be an attractive alternative to Gd(III) in the future. [Brief description of the drawings]

[0031] [Figure 1] FIG. 1 shows the dissociation rates of Mn(II)-based chelates tested by the method of Example 15. [Diagram 2] FIG. 1 shows 1H NMRD profiles recorded for Mn(II)-based chelates measured by the method described in Example 14. [Diagram 3] FIG. 1 shows 1H NMRD profiles recorded for Mn(II)-based chelates measured by the method described in Example 14. [Figure 4] FIG. 1 shows the results of transmetallation experiments carried out on prior art Mn-chelate compounds described in Example 15. [Diagram 5] FIG. 1 shows the results of transmetallation experiments carried out on prior art Mn-chelate compounds described in Example 15. [Figure 6] FIG. 1 shows a comparison of transmetallation results obtained for a prior art compound and a specific compound of the invention described in Example 15. [Figure 7] FIG. 1 shows a comparison of transmetallation results obtained for a prior art compound and a specific compound of the invention described in Example 15. [Figure 8] FIG. 1 shows the time dependence curves of longitudinal relaxation times (i.e., T1) for compounds of the present invention. [Figure 9] FIG. 1 shows the transformation caused by the competition between Cu2+ and the Mn chelate compounds of the present invention compared to the prior art Mn chelate compounds. [Figure 10] FIG. 1 shows the transformation caused by the competition between Cu2+ and the Mn chelate compounds of the present invention compared to the prior art Mn chelate compounds. [Figure 11] FIG. 1 shows the results obtained for the transmetallation reaction with Zn2+ by Mn chelates of the prior art compared with the compounds of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] In order to more clearly and concisely describe and illustrate the subject matter claimed, the present specification and Definitions and example embodiments are provided for specific terms used throughout the claims. The instances of specific terms herein are to be considered as non-limiting examples. It should be.

[0033] term" containing )"or" contains )" The terms have their accustomed meaning throughout this application and are intended to be used interchangeably with the term "compound" as used herein, unless the agent or composition has the essential recited characteristics. It must have the features or components, but other features or components may also be present. The term " containing )" is a preferred sub As a set, a composition has the recited components, with no other features or components present. " means to consisting essentially of ly of )"

[0034] " Alkyl " means, alone or in combination, a compound of the general formula C n H 2n+1 Direct It refers to a single chain or branched alkyl group. Examples of such groups are methyl, ethyl, and isopropyl.

[0035] term" Hydroxyl " refers to the group --OH.

[0036] term" Hydroxyalkyl " means any of the groups defined above, including a hydroxyl substituent as defined above. It refers to an alkyl group as defined above.

[0037] term" Aryl " refers to a functional group or substituent derived from an aromatic ring, usually an aromatic hydrocarbon. Examples of substituents include phenyl and pyridyl. The aryl group of the invention contains between 0 and 3 heteroatoms selected from O, N and S. It is an aromatic six-membered ring.

[0038] term" halogen "or" Halo " is selected from fluorine, chlorine, bromine, or iodine; It means a substituent.

[0039] term" Carbohydrate portion " refers to aldehyde or ketone derivatives of polyhydric alcohols, These include monosaccharide, disaccharide and oligosaccharide residues. These include lucose, glucose and sucrose residues.

[0040] In one embodiment of the compound of formula I, each R 1 is C 1~12 With hydroxyalkyl be.

[0041] In one embodiment of the compound of formula I, each R 1 is C 3~6 Hydroxyalkyl do.

[0042] In one embodiment of the compound of formula I, each R 1 is a C6 hydroxyalkyl.

[0043] In one embodiment of the compound of formula I, each R 1 are, independently,

[0044] [ka] in which in each case the asterisk indicates the point of attachment to the remainder of the compound of formula I. The compound is selected from the group consisting of:

[0045] In one embodiment of the compound of formula I, each R 1 are, independently,

[0046] [ka] in which in each case the asterisk indicates the point of attachment to the remainder of the compound of formula I. The compound is selected from the group consisting of:

[0047] In one embodiment of the compound of formula I, each R 1 is halo and -C(=O)-NH- C 1~6 C substituted with one or more substituents selected from hydroxyalkyl 3~6 It is aryl.

[0048] In one embodiment of the compound of formula I, 3~6 Aryl is phenyl.

[0049] In one embodiment of the compound of formula I, the halo is iodo.

[0050] In one embodiment of the compound of formula I, -C(=O)-NH-C 1~6 Hydroxyalkyl The alkyl group is -C(=O)-NH-CH2-C(OH)-CH2-C(OH).

[0051] In one embodiment of the compound of formula I, each R 1 teeth,

[0052] [ka] where the asterisk indicates the point of attachment to the remainder of the compound of formula I. It is.

[0053] In one embodiment of the compound of formula I, each R 1 teeth,

[0054] [ka] where the asterisk indicates the point of attachment to the remainder of the compound of formula I. It is.

[0055] In one embodiment of the compound of formula I, each R 1 is the same.

[0056] In one embodiment of the compound of formula I, each R 2 is C 1~3 It is an alkyl.

[0057] In one embodiment of the compound of formula I, each R 2 is methyl.

[0058] In one embodiment of the compound of formula I, each R 2 is hydrogen.

[0059] In one embodiment of the compound of formula I, each R2 is C 1~20 With hydroxyalkyl be.

[0060] In one embodiment of the compound of formula I, each R 2 is C 1~6 Hydroxyalkyl Each R 2 C 1~6 When R is hydroxyalkyl, in one embodiment, 1 C 1~6 In another embodiment, R 2 and R 1 is the same.

[0061] In one embodiment of the compound of formula I, each R 2 is the same.

[0062] In one embodiment of the compound of formula I, each n is an integer from 1 to 3.

[0063] In one embodiment of the compound of formula I, n is 1.

[0064] In one embodiment of the compound of formula I, n is 2.

[0065] In one embodiment of the compound of formula I, each n is 3.

[0066] In one embodiment of the compound of formula I, R 3 is C 1~3 It is an alkyl.

[0067] In one embodiment of the compound of formula I, R 3 is methyl.

[0068] In one embodiment of the compound of formula I, R 3 is defined herein as -(CH2) m - C(=O)-NR 5 R 6 It is.

[0069] In one embodiment of the compound of formula I, R 5 is herein referred to as R 1 is defined for This is true.

[0070] In one embodiment of the compound of formula I, R 6 is herein referred to as R 2 is defined for This is true.

[0071] In one embodiment of the compound of formula I, m is 3.

[0072] In one embodiment of the compound of formula I, n is 2.

[0073] In one embodiment of the compound of formula I, R 4 represents 0 substituents.

[0074] In one embodiment of the compound of formula I, R 4 represents one or two hydroxy groups.

[0075] In one embodiment of the compound of formula I, R 4 The pyridyl ring has two meta-hydroxy groups. Represents a group.

[0076] In one embodiment, the compound of formula I contains at least four hydroxy groups.

[0077] In one embodiment, the compound of formula I contains 4 to 15 hydroxy groups.

[0078] In one embodiment, the compound of formula I contains 5 to 10 hydroxy groups.

[0079] In one embodiment of the compound of the present invention, Mn is 52 Mn and 54 From the group containing Mn In one embodiment, the Mn isotope is selected from 54 Mn .

[0080] Non-limiting examples of compounds of formula I are the following compounds:

[0081] [ka] Mn chelate 1 racemic

[0082] [ka] Mn chelate 2 racemic

[0083] [ka] Mn chelate 3 racemic

[0084] [ka] Mn chelate 4 racemic

[0085] [ka] Mn chelate 5 racemic

[0086] [ka] Mn chelate 6 racemic

[0087] [ka] Mn chelate 7 racemic

[0088] [ka] Mn chelate 8 racemic

[0089] [ka] Mn chelate 9 racemic

[0090] [ka] Mn chelate 10 racemic

[0091] [ka] Mn chelate 11 racemic

[0092] [ka] Mn chelate 5a racemic

[0093] [ka] Mn chelate 7a racemic

[0094] [ka] Mn chelate 10a racemic In the compounds of formula I, the carbon attached to the carboxylate arm is a stereogenic center. The compounds of formula I of the invention may be used as racemic mixtures or as enantiomerically enriched mixtures. The racemic mixture may be provided as is, or the racemic mixture may be separated using well known techniques, The individual enantiomers may be used alone. In one embodiment, the compound of formula I is In one embodiment, the compound of formula I is a diastereomerically pure compound. The product is diastereomerically pure.

[0095] A non-limiting example of a diastereomerically pure compound of formula I is the following compound:

[0096] [ka] Mn chelate 3

[0097] [ka] Mn chelate 4

[0098] [ka] Mn chelate 5

[0099] [ka] Mn chelate 7

[0100] [ka] Mn chelate 9

[0101] [ka] Mn chelate 10

[0102] [ka] Mn chelate 11

[0103] [ka] Mn chelate 5a

[0104] [ka] Mn chelate 7a

[0105] [ka] Mn chelate 10a Hydrophilic derivatization to obtain the compounds of the present invention is accomplished by an amide bond with an aliphatic linker. This is achieved by the non-coordinating amide group being too far away from the manganese ion. Therefore, it will not coordinate. 3 The exact length of the non-coordinating linker is very important. If it is too short (i.e., m=1 in formula I), the amide group becomes manganese iridium. There is a risk of coordination to the ion, thus hindering the access of water molecules and decreasing the overall relaxivity of the complex. There is a risk that the value of the non-coordinated phosphorus bonded to the carboxymethyl arm (coordinating group) will decrease dramatically. The length of the car is such that the same "arm" facilitates two coordination groups. (the coordination angle would be excessively distorted), so it can be short (i.e., n=0 in formula I). ).

[0106] Compounds of formula I can be prepared from commercially available starting materials by a number of synthetic routes known to those skilled in the art. The mannansulfonyl groups can be used for incorporation into chelates when making the compounds of the invention. Suitable sources of Mn include carbonate (MnCO3), oxide (MnO), acetate (Mn (OAc)2), chloride (MnCl2), hydroxide (Mn(OH)2), oxalate (M nC2O4), formate (Mn(HCO2)2) and nitrate (Mn(NO3)2) salts The following generalized procedure can be used and / or easily adapted to produce compounds of formula I: The compound can be obtained.

[0107] [ka] In short, A: Tosylation of aminoethanol gives aziridines (Carrillo, A rkivoc, 2007).

[0108] B: Aminobutanoic acid (Sigma Aldrich catalogue 56-12-2) aziridine In one embodiment, the aziridination of methylamine proceeds in pure acetonitrile. In one embodiment, the amino acid uses some base to activate the amine. Optionally, the acid functionality can be protected as an ester.

[0109] C: 2,6-Bis(chloromethyl)-pyridine (Sigma Aldrich catalogue) In one embodiment, this step is carried out in acetonitrile. with potassium carbonate as the base.

[0110] D: Detosylation, in one embodiment using concentrated sulfuric acid. In one embodiment, this step is Progress quantitatively.

[0111] E: Bromination based on the method described in the literature (Henig, J., Toth, E., En gelmann, J., Gottschalk, S., & Mayer, Ha(201 0).Inorganic Chemistry, 49(13), 6124-38).

[0112] F: Alkylation of polyamines. In one embodiment, this step is carried out in aqueous solution. In another embodiment, when the secondary halide reacts slowly (primary alkyl halide (Proceeds smoothly), synthesize bis-ester (E), and switch to organic solvent to increase the reaction rate. It is possible to improve it.

[0113] G: Complexation using MnCl2. Precipitate excess Mn using base.

[0114] H: Activation of carboxylates with peptide reagents. In one embodiment, these reagents are DCI and / or HOBT (as described in European Patent No. 2457914B1) Conjugation via a suitable amine (e.g., meglumine).

[0115] The compound of formula I is R 1 In addition, triiodiated phenyl etc. If the compound contains a substituted aryl, the following reaction scheme can be used or adapted to produce the compound: You can get:

[0116] [ka] A non-limiting selection of compounds of the present invention may be synthesized as described in Examples 1-10 below. The prior art compounds were synthesized as described in Example 11. Characterized in vitro and / or in vivo as described in Examples 12-15.

[0117] Suitable methods for the in vitro characterization of chelate stability can be found in the literature. (Idee, J.-M. Journal of Magnetic Resonance) e Imaging: JMRI, 2009, 30(6), 1249-58 and Bara nyai,Z.Chemistry-A European Journal,2015 ,21(12),4789-4799). Other suitable methods include the use of physiological media ( In vitro studies monitoring the transmetallation inactivation of human serum or plasma Another suitable method for assessing transmetallation inactivity is the use of chelated metal The objective of this study will be to measure the retention of metal ions in vivo after injection of the chelate. It is known that these drugs usually undergo very rapid clearance kinetics.

[0118] In one aspect of the invention, the compounds of formula I are provided as pharmaceutical compositions.

[0119] " Pharmaceutical Compositions " refers to a compound of the present invention in a form suitable for mammalian administration together with a biocompatible carrier. It is a composition containing. Biocompatible Carriers " is intended to ensure that the resulting composition is physiologically tolerable. i.e., so that it may be administered to the mammalian body without toxicity or undue discomfort. A fluid, especially a liquid, that suspends or dissolves the compound of formula I (this is the term Suitable for mammalian administration did " may be understood as a definition of

[0120] The pharmaceutical compositions of the present invention are useful in magnetic resonance imaging (MRI) of the human and non-human animal body. It is therefore suitable for use as a magnetic resonance (MR) contrast agent.

[0121] In one embodiment, the pharmaceutical compositions of the present invention contain one or more pharma- ceutical acceptable excipients. These preferably do not interfere with the manufacture, storage or use of the final composition.

[0122] Non-limiting examples of suitable pharma- ceutically acceptable excipients include buffers, stabilizers, antioxidants, and the like. Inhibitors, osmolality regulators, pH adjusters, excess keyland, and physiologically tolerated inhibitors These and other suitable excipients are well known to those skilled in the art. See, for example, International Publication No. WO 199000380, the contents of which are incorporated herein by reference. 4, European Patent Application Publication No. 0463644, European Patent Application Publication No. 0258616 and and U.S. Patent No. 5,876,695. The pharmaceutical compositions of the present invention are, in one embodiment, In the form, it is in a form suitable for parenteral administration, for example for injection. The compositions may be administered using a physiologically acceptable vehicle, within the skill of the art. For example, the formulation may be prepared by adding a pharma- ceutical acceptable excipient. The compound of formula I is suspended or dissolved in an aqueous medium, and the resulting solution or suspension is then may be sterilized.

[0123] A non-limiting example of a suitable buffering agent is tromethamine hydrochloride.

[0124] term" Excessive Keyland " is a free The paramagnetic ion (manganese) can be removed, but the paramagnetic ion retained within the complex of the present invention is The manganese ion is defined as a compound that is not removed. Small amounts are necessary for human health. However, excessive exposure to free manganese ions can lead to the development of “Manganese syndrome,” a condition that resembles Parkinson’s disease. However, Mn and other The basic problem with metal contrast agents is their chelation stability. is an important property that reflects the possibility of releasing free metal ions in vivo. There is no correlation between the amount of excess Kerlan in the drug formulation and the amount of paramagnetic metal deposited in the animal model. It is known that there is a relationship between ging;27(5):955-62). Thus, in another embodiment, the post-injection formulation To act as a Mn scavenger to reduce or prevent the release of Mn from The amount of excess keyland that can be obtained is selected. The optimal amount of free keyland is determined by appropriate physicochemical properties. and providing pharmaceutical compositions having the desired properties (i.e., viscosity, solubility, and osmolality). This avoids the toxic effects of too much free ketamine, such as zinc depletion. No. 876,695 describes an excess of linear chelates, particularly free DTPA, which is the subject of the present invention. These are non-limiting examples of suitable keyland derivatives for use in pharmaceutical compositions of the present invention. Magnevist™, Vasovist™ or Primovist™ (trademark) and other products. WO 2009103744 discloses the exact amount of free chelate was added to give a very small excess of said chelate and zero concentration of free lanthanide. A similar formulation strategy based on having

[0125] The physiologically tolerable ions, in one embodiment, are calcium chloride, ascorbic acid Calcium or sodium salts such as calcium, calcium gluconate or calcium lactate The cations may be selected from physiologically tolerable ions, including cation salts.

[0126] Parenterally administrable forms must be sterile and free of physiologically unacceptable agents. and must have low osmolality to minimize irritation or other adverse effects upon administration. Therefore, the pharmaceutical composition must be isotonic or slightly hypertonic. Non-limiting examples of suitable vehicles include those customarily used for administration of parenteral solutions. Aqueous vehicles, such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection , Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, and Remin gton's Pharmaceutical Sciences, 22 nd Edit ion (2006 Lippincott Williams & Wilkins) and National Medicines Guide ( https: / / books.google.com / books?id =O3qixPEMwssC&q=THE+NATIONAL+FORMULARY&d q=THE+NATIONAL+FORMULARY&hl=en&sa=X&ved= 0CC8Q6AEwAGoVChMImfPHrdTqyAIVJfNyCh1RJw_ E ) and other solutions described therein.

[0127] Regarding the pharmaceutical compositions of the present invention that are administered parenterally, i.e., by injection, their preparation This includes removal of organic solvents, biocompatible buffers and any additional additives such as excipients or buffers. For parenteral administration, the pharmaceutical composition may further include steps such as adding ingredients to the composition. Steps are also required to ensure that the is sterile and non-pyrogenic.

[0128] In another embodiment, the present invention relates to the generation of MR images and / or MR spectra. The present invention provides a method of treating a patient suffering from atopic dermatitis comprising administering a compound of formula I as defined herein.

[0129] Methods and targets of administration envisaged as appropriate in the context of the present invention are those relating to pharmaceutical compositions. As described hereinbefore, the administration of the compounds of formula I is preferably carried out parenterally. The intravenous route is preferably used to deliver the compound to the entire body of the subject. Furthermore, intravenous administration represents the most effective method for administering the drug without substantial physical intervention or intervention. The compounds of formula I according to the invention preferably have the above-defined structure and do not pose any significant health risk. The method of the present invention also includes administering a compound of the present invention as a pharmaceutical composition. It can be understood that the present invention includes steps (ii) to (iii) performed on a subject. In one embodiment, the pharmaceutical composition is used to enhance contrast in a method of magnetic resonance imaging (MRI). For further details on MRI methods, the reader is referred to, for example, agnetic resonance imaging:Physical and B Biological Principles" (4 th Edition 2015 E lsevier,Stewart Carlyle Bushong&Geoffrey Clarke, Eds., Chapter 27, "Contrast Agents and "Gnomatic Resonance Imaging" or "Contrast A gents I:Magnetic Resonance Imaging” (2002 Springer-Verlang, Werner Krause, Ed. Reference is made to the general general knowledge in the art.

[0130] The methods of the present invention are useful for studying biological markers or processes in healthy subjects. or for having a condition associated with abnormal expression of a biological marker. The method may be used in subjects known or suspected to have a symptom. When used to image a subject known or suspected of having said condition, The present invention has utility in methods for diagnosing

[0131] The method of the present invention detection " step comprises detecting a signal emitted by the compound of formula I, The detection step involves detecting the signal with a detector sensitive to the signal. It can also be understood as.

[0132] The method of the present invention Generate " step is performed by a computer, and the computer A reconstruction algorithm is applied to the acquired signal data to generate a data set. The data set may be manipulated to obtain one or more images and / or signal locations and and / or generating one or more spectra indicative of the quantity.

[0133] "The present invention subject " may be any human or animal subject. In one embodiment, the present invention The subject of interest is a mammal. In one embodiment, the subject is an in vivo intact mammal. In another embodiment, the subject of the present invention is a human.

[0134] This written description is provided for the purpose of disclosing the invention, including the best mode, and Those skilled in the art will be familiar with making and using the device or system, as well as the methods incorporated therein. Examples are used to enable the invention to be practiced, including implementation. The patentable scope of the invention is defined in the claims, which are within the scope of the principles of the art. Other examples that come to mind may be included. Such other examples are within the scope of the claims. If the term has structural elements that do not differ from the literal meaning of the term, or if they are not included in the scope of the claims, If the scope of the claims includes equivalent structural elements that do not substantially differ from the literal meaning of the claims, All patents and patent applications mentioned herein are intended to be within the scope of the present invention. are incorporated herein by reference in their entireties as if individually incorporated.

[0135] Brief description of the embodiment Example 1 describes the synthesis of Mn chelate 3.

[0136] Example 2 describes the synthesis of Mn chelate 4.

[0137] Example 3 describes the synthesis of Mn chelate 5.

[0138] Example 4 describes the synthesis of Mn chelate 7.

[0139] Example 5 describes the synthesis of Mn chelate 9.

[0140] Example 6 describes the synthesis of Mn chelate 10.

[0141] Example 7 describes the synthesis of Mn chelate 11.

[0142] Example 8 describes the synthesis of Mn chelate 5a.

[0143] Example 9 describes the synthesis of Mn chelate 7a.

[0144] Example 10 describes the synthesis of Mn chelate 10a.

[0145] Example 11 describes the synthesis of a prior art Mn chelate.

[0146] Example 12 shows an in vivo study in rats. 54 Mn biodistribution studies are described.

[0147] Example 13 illustrates the characterization of the aqueous solubility of compounds of the invention.

[0148] Example 14 shows the in vitro proton relaxivity and nuclear magnetic relaxation dispersion of the compounds of the present invention. (NMRD) profile is described.

[0149] Example 15 describes experiments performed to determine the dissociation rates of compounds of the invention.

[0150] List of Abbreviations Used in the Examples AcN Acetonitrile DMSO Dimethyl sulfoxide EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide EtOAc Ethyl acetate EtOH Ethanol h time HOBt Hydroxybenzotriazole MeOH Methanol NMR nuclear magnetic resonance NMRD nuclear magnetic relaxation dispersion Working Example Example 1: Synthesis of chelate 3 Example 1(i): 4-(benzyloxy)-4-oxobutan-1-aminium 4-methyl Synthesis of ethylbenzenesulfonate

[0151] [ka] A 2 L three-neck flask was equipped with a mechanical stirrer, a Dean-Stark trap, a reflux condenser, and The flask was equipped with a nitrogen inlet and a 500 rpm kettle. The flask was charged with 4-aminobutanoic acid (41.522 g, 0.01 ml). .403 mol), p-toluenesulfonic acid (91.912 g, 0.048 mol), and and benzyl alcohol (201 mL). The resulting cloudy solution was refluxed for 14 h. At the end of the reflux period, n-hepate (175 mL) was added to the hot reaction mixture. The reaction was allowed to cool to ambient temperature and the resulting white crystals were isolated by vacuum filtration. The product was isolated by filtration and recrystallized from 6:1 ethyl acetate / n-hexane to give 124.2 g (8.5 g, 8.5% yield). 4%) of the desired product as a white solid. 1 H NMR (400 MHz, CDCl3, δ)7.71(5H,d), 7.31(5H,m), 7.13(2H,d), 5.02( 2H,s), 2.87(2H,m), 2.32(5H,m), 1.85(2H,m).

[0152] Example 1(ii): 4-(bis(2-(4-methylphenylsulfonamido)ethyl) Synthesis of benzyl aminobutanoate

[0153] [ka] A 2 L jacket equipped with a 4-blade anchor-type stirring paddle, reflux condenser, and nitrogen inlet Into a reactor equipped with a heater, N-tosylaziridine (107.7 g, 0.546 mol) and Water acetonitrile (870 mL) was charged. Amino-1-aminium 4-methylbenzenesulfonate (100g, 0.274mol) and anhydrous acetonitrile (500 mL) were then added to give an off-white suspension. Propylamine (47.6 mL, 0.274 mol) was added and the reaction was heated at 40° C. for 16 h. The reaction was then cooled to 22.5° C. and stirred for an additional 49 hours. The suspension was vacuum filtered and the clear yellow filtrate was concentrated to dryness. The crude material was purified by silica gel chromatography. Graphy (50% hexane in EtOAc to 10% hexane in EtOAc; both eluents The crude product contained 1% triethylamine) to give 89.7 g (54%) of the desired product. The product was obtained as a colorless oil. 1 H NMR (400MHz, CD2Cl2, δ)7 .74(4H,d), 7.35(9H,m), 5.13(2H,m)5.10(2H,s ), 2,85(4H,m), 2.41(10H,m), 2.23(4H,m), 1.60 (2H,m).

[0154] Example 1(iii): Synthesis of protected cyclic 3-arm chelates

[0155] [ka] In a 3 L, three-necked round-bottom flask equipped with a mechanical stirrer, reflux condenser, and nitrogen inlet, Glass sphere with a diameter of 86 mm, 4-(bis(2-(4-methylphenylsulfonamido)ethyl )amino)benzyl butanoate (143.9 g, 0.245 mol) and 2,6-bis( (chloromethyl)pyridine (43.1 g, 0.245 mmol) was added. Tolyl (1.632 L) was added, followed by anhydrous potassium carbonate (135.5 g, 0.980 mol) was added and the resulting solution was heated at 80° C. for 47 hours. The mixture was cooled to ambient temperature and stirred for an additional 65 hours. Anhydrous potassium carbonate (67.0 g, 0.4 85 g) was added and the reaction was stirred at ambient temperature for 27 hours. The insoluble potassium carbonate was removed by vacuum filtration. The crude material was purified by silica gel chromatography. Raffin (100% CH2Cl2 to 10% MeOH in CH2Cl2; both eluents are 1% (which contained triethylamine) to give 70.9 g (42%) of the desired product. Obtained as a white foam. 1 H NMR (400MHz, CD2Cl2, δ)7.72(5 H,m), 7.34(9H,m), 7.26(2H,d), 5.09(2H,s), 4. 31(4H,s), 3.07(4H,m), 2.43(6H,s), 2.28(8H,m ), 1.61(2H,m).

[0156] Example 1(iv): Synthesis of deprotected 3-arm cyclic chelates

[0157] [ka] In a 3 L, three-neck round-bottom flask equipped with a mechanical stirrer, reflux condenser, and stopper, Cyclic 3-arm chelate (70.5 g, 92.3 mmol) and concentrated H2SO4 (282 m L) and heated at 100° C. for 19 hours. The resulting black solution was cooled to ambient temperature and The pH was adjusted to 7 with 50 wt % NaOH in water. MeOH (1 L) was added and the solids were dissolved in water. The filtrate was concentrated to dryness to leave a black residue, which was dissolved in MeOH (5 The mixture was ground with 0.00 mL of 100% ethanol at 60° C. for 1 hour. The insoluble material was removed by vacuum filtration, and the filtrate was The resulting light brown semi-solid was dissolved in MeOH (1 L) and the pH was adjusted to 10 with concentrated H2S. The solution was then adjusted to approximately 1 with O4 and stirred at ambient temperature for 18 hours. The solution was then stirred for 25 hours. The mixture was heated to 60° C. The insoluble material was removed by vacuum filtration and the pH of the filtrate was adjusted with potassium carbonate. The undissolved potassium carbonate was removed by vacuum filtration, and the filtrate was concentrated to dryness. The resulting off-white solid was triturated with anhydrous acetonitrile (1 L) to remove the insoluble material. The filtrate was concentrated to dryness to give 25.3 g (89.6%) of the desired product. Object (ESI:m / z=306(M+H + )) was obtained as a white solid.

[0158] Example 1(v): Synthesis of protected Mn3-arm C5 chelate

[0159] [ka] In a 100 mL round bottom flask equipped with a magnetic stir bar and reflux condenser, add the deprotected 3 Arm cyclic chelate (2.776 g, 9.06 mmol) and anhydrous acetonitrile (6 0.4 mL). Then triethylamine (3.16 mL, 22.7 mmol) followed by dimethyl 2-bromopentanedioate (4.982 g, 20.8 mmol). l) was added and the resulting solution was heated at 65° C. for 20 hours. A second aliquot of dioate (1.36 g, 5.7 mmol) was added and the mixture was stirred for another 11 p.m. Heating was continued for 1 h. The solvent was removed in vacuo and the crude material was 18 Silica gel (30% acetone in water) nitrile) to give 2.883 g (51%) of the desired product (ESI: m / z=623 (M+H + )) was obtained as a yellow oil.

[0160] Example 1(vi): Synthesis of deprotected Mn3-arm C5 chelate

[0161] [ka] In a 500 mL round bottom flask equipped with a magnetic stir bar, Charge the protected Mn3 arm C5 chelate (14.010 g, 22.5 mmol), 12.5 M NaOH (18.0 mL) was added. The resulting solution was incubated at ambient temperature for 18 h. The pH was then adjusted to 6 with concentrated HCl and the solvent was removed in vacuo. The crude residue was 18 Purify with silica gel (100% water to 15% AcN in water) to obtain 12.43 g (100%) Target product (ESI:m / z=553(M+H + )) was obtained as a yellow oil.

[0162] Example 1(vii): Synthesis of Mn3-arm C5 chelate

[0163] [ka] In a 1 L three-neck round bottom flask equipped with a magnetic stir bar, add the deprotected Mn3 arm C5 chiral phosphate (12.43 g, 22.5 mmol), manganese chloride tetrahydrate (8.90 g, 45. The resulting solution was stirred at ambient temperature for 12.5 hours. The solution was stirred for 1 h. The pH was then adjusted to 6 and the reaction was heated at 75° C. for 7 h. The mixture was cooled to 30° C. and the pH was adjusted to 8 with saturated aqueous sodium carbonate. The crude residue was removed by empty filtration and the filtrate was concentrated to dryness in vacuo. 18 Silica gel (10 0% water) to give 13.33 g (98%) of the desired product (ESI: m / z=606( M+H + )) was obtained as a yellow solid.

[0164] Example 1(viii): Synthesis of Mn chelate 3

[0165] [ka] In a 100 mL three-neck flask equipped with a magnetic stir bar, add Mn3-arm C5 chelate (1. The mixture was charged with N-methyl-D- Glucamine (1.54 g, 7.9 mmol) was added, followed by EDCI-HCl (1.6 4 g, 8.6 mmol) was added and the pH was adjusted to 6.4 with 1.0 M HCl. t hydrate (0.140 g, 1.0 mmol) was added and stirred at ambient temperature for 18 h. The pH was maintained at 6. N-methyl-D-glucamine (0.77 g, 3.9 mmol) and and EDCI-HCl (0.82 g, 4.3 mmol) were added and stirred at ambient temperature for 8 h. The pH was maintained at 6. EDCI-HCl (0.42 g, 2.2 mmol) was added. The mixture was stirred at ambient temperature for 17 hours. All solvent was then removed in vacuo to give a brown oil. The rest, this, C 18 Purify with silica gel (100% water to 30% AcN in water) to obtain 1.6 g (56%) of the desired product (ESI: m / z = 1138 (M+H + )) was obtained.

[0166] Example 2: Synthesis of Mn chelate 4 Example 2(i): N,N'-((methylazanediyl)bis(ethane-2,1-diyl) )) Synthesis of bis(4-methylbenzenesulfonamide)

[0167] [ka] In a 1 L round bottom flask equipped with a magnetic stir bar, add N-tosylaziridine (49 g, 248 The mixture was charged with 41% aqueous methylamine (12 mmol) and AcN (450 mL). L, 121 mmol) was added and stirred at ambient temperature for 36 hours. A second aliquot (1.7 g, 8.62 mmol) was added and incubated at ambient temperature for an additional 48 h. The solvent was removed in vacuo and the crude residue was recrystallized from EtOH to give 45 g (87%). of the desired product as a white solid. 1 H NMR (400 MHz, DMSO-D6, δ )7.68(4H,m), 7.36(6H,m), 2.75(4H,t), 2.38(6 H,s), 2.22(4H,t), 1.93(3H,s).

[0168] Example 2(ii): Synthesis of protected cyclic two-arm chelates

[0169] [ka] In a 12 L three-neck round-bottom flask equipped with a reflux condenser and mechanical stirrer, add N,N'-(( Methylazanediyl)bis(ethane-2,1-diyl)bis(4-methylbenzenesulfonyl) Charge the flask with 2,4-hexanediamine (93 g, 218.5 mmol) and AcN (8.3 L). 6-Bis(chloromethyl)pyridine (38.5 g, 218.5 mmol) was added, and the resulting The resulting solution was heated at 80° C. for 16 h. The reaction mixture was cooled to ambient temperature and crystallization began. The solvent was removed in vacuo until the crystals were recovered by vacuum filtration, yielding 86.9 g (7 5%) of the desired product was obtained as a white solid (ESI: m / z=530 (M+H + )).

[0170] Example 2(iii): Synthesis of deprotected two-arm cyclic chelates

[0171] [ka] In a 1 L three-neck round bottom flask equipped with a mechanical stirrer, the protected cyclic two-arm chelate ( Charge 100 ml of concentrated sulfuric acid (150 g, 284 mmol) and 100 ml of concentrated sulfuric acid (150 mL, 4.69 mol). The solution was poured onto ice and 50% by weight NaOH in water was added to the mixture. The pH was adjusted to 7.4, forming a white solid. AcN (200 mL) was added and The white solid was removed by vacuum filtration. The filtrate was concentrated to dryness to give a brown foam. was dissolved in water (200 mL) and purified with Amberlite A26 resin in the hydroxide form to give 6 Obtained 1 g (98%) of the desired product as a brown solid. 1 H NMR (400 MHz, C D3CN, δ)7.56(1H,m), 7.03(2H,m), 3.76(4H,s), 2.47(4H,m), 2.19(3H,s), 1.95(4H,s).

[0172] Example 2(iv): Synthesis of protected Mn2-arm C5 chelates

[0173] [ka] In a 500 mL round bottom flask equipped with a magnetic stir bar, add the deprotected 2-arm cyclic chelate. (20.0 g, 90.8 mmol; obtained according to Example 2(iii)) and AcN( Diisopropylethylamine (38.7 mL, 217 mmol) was added. ) and dimethyl 2-bromopentanedioate (47.7 g, 199.7 mmol) and the resulting solution was stirred at 65° C. for 20 hours. Diisopropylethylamine (9. 75 mL, 54.6 mmol) and dimethyl 2-bromopentanedioate (11.8 g, 49.4 mmol) was added and the resulting solution was stirred at 65° C. for an additional 19 h. The solvent was removed in vacuo leaving a red oil, which was then dissolved in water (300 mL). The EtOAc layer was then dissolved and washed with EtOAc (300 mL). This was extracted with 100 ml of ethyl acetate and combined with the first aqueous layer, and the water was removed in vacuo to leave a red oily material which was Used without further purification.

[0174] Example 2(v): Synthesis of Mn2-arm C5 chelate

[0175] [ka] In a 1 L round bottom flask equipped with a magnetic stir bar, add the protected Mn2 arm C5 chelate ( Sodium hydroxide (48.7 g, 90.8 mmol) and water (450 mL) were charged. (29.1 g, 726 mmol) was added and stirred at ambient temperature for 2 hours. The reaction mixture was stirred at 100° C. for 2 hours. The aqueous layer was washed with tOAc (250 mL) and the layers were separated. The aqueous layer was collected and washed with manganese chloride tetrahydrate (19.6 g, 99 mmol). The pH was adjusted to 7.1 with 6M NaOH and stirred at ambient temperature for 17 hours. After that, the mixture was stirred at 90° C. for 2.5 hours. After cooling to ambient temperature, the pH was adjusted to 50% by weight of NaO The pH was adjusted to 10.1 with H2O, and a fine brown precipitate was formed. The precipitate was heated at 3000rcf for 20 The mixture was centrifuged for 1 min, the supernatant was collected and evaporated to dryness in vacuo. The residue was diluted with MeOH (127 mL) at 40° C. for 1.5 hours. The insoluble white solid was triturated with 3000 rcf The supernatant was concentrated to dryness in vacuo to give an off-white solid. This is C 18 Purification on silica gel (3% AcN in water) gave 36.8 g (75%) of the desired product. The product was obtained as an off-white solid (ESI: m / z=534 (M+H + )).

[0176] Example 2(vi): Synthesis of Mn chelate 4

[0177] [ka] In a 250 mL three-neck round-bottom flask equipped with a magnetic stir bar, add Mn2-arm C5 chelate ( 4.40 g, 7.27 mmol) and water (76.5 mL). -glucamine (2.98 g, 15.3 mmol) was added, followed by EDCI-HCl (3 .30g, 17.2mmol) and HOBt hydrate (0.20g, 1.47mmol) HCl or 1.0 M as needed was added while stirring at ambient temperature for 7 hours. The pH was maintained at 6 by adding M NaOH. EDCI-HCl (1.62 g, 8.4 5 mmol) was added and the pH was maintained at 6 with stirring at ambient temperature for 20 hours. A mixture of 100 mL of EDCI-HCl (0.8 g, 3.84 mmol) and 10 mL of EDCI-HCl (0.8 3 g, 4.32 mmol) was added and the pH was maintained at 6 with stirring at ambient temperature for 3 days. The reaction solution was concentrated in vacuum to dryness, and the crude product was 18 Silica gel (100% water to 20% in water) % AcN) to give 3.66 g (57%) of the desired product as a pale yellow solid ( ESI: m / z=888 (M+H + )).

[0178] Example 3: Synthesis of Mn chelate 5

[0179] [ka] In a 50 mL two-neck flask equipped with a magnetic stir bar, add D-glucamine (0.713 g, 3 The resulting solution was adjusted to a pH of 1.0M. Adjust the pH to 7.4 with HCl and dilute the Mn2-arm C5 chelate (1.00 g, 1.87 mmol) ; obtained according to Example 2(v)) was added, followed by EDCI-HCl (0.848 g, 4 0.42 mmol) and HOBt hydrate (0.121 g, 0.787 mmol) were added. The mixture was stirred at ambient temperature for 8 hours with 1.0 M HCl or 1.0 M NaCl, as needed. OH was added to maintain the pH at 6. D-glucamine (0.359 g, 1.98 mmol) l) and EDCI-HCl (0.433 g, 2.26 mmol) were added and the mixture was stirred at ambient temperature. The reaction solution was concentrated to dryness in vacuo to give the crude product. , C 18 Purify with silica gel (100% water to 20% AcN in water) to obtain 0.782 g (48 %) of the desired product was obtained as a pale yellow solid (ESI: m / z=860 (M+H + )).

[0180] Example 4: Synthesis of Mn chelate 7

[0181] [ka] In a 50 mL two-neck flask equipped with a magnetic stir bar, add 5-amino-N,N'-bis(2, 3-Dihydroxypropyl)isophthalamide hydrochloride (1.432 g, 3.94 mmol) ) and water (19.7 mL). The pH of the resulting solution was adjusted to 6, and Mn2Ar was added. C5 chelate (1.005 g, 1.88 mmol; obtained according to Example 2(v)) was added. followed by EDCI-HCl (0.858 g, 4.48 mmol) and HOBt hydrate. (0.108 g, 0.799 mmol) was added. The mixture was stirred at ambient temperature for 4.5 hours. Add 1.0 M HCl or 1.0 M NaOH as needed to maintain the pH at 6. EDCI-HCl (0.868 g, 4.53 mmol) was added and the mixture was stirred at ambient temperature for 16 h. The pH was maintained at 6 with stirring for 2 h. EDCI-HCl (0.853 g, 4.44 mm ol) was added to maintain the pH at 6 with stirring for 7 hours at ambient temperature. The reaction solution was vacuum The crude product was concentrated to dryness using 18 Purified with silica gel (100% water to 25% AcN in water) This gave 0.600 g (28%) of the desired product as a pale yellow solid (ESI: m / z =1152(M + )).

[0182] Example 5: Synthesis of Mn chelate 9

[0183] [ka] In a 25 mL two-neck flask equipped with a magnetic stir bar, add diethanolamine (0.207 g , 1.97 mmol) and water (9.86 mL) were charged. The pH of the resulting solution was adjusted to 1. Adjust the pH to 7 with 0.05 M HCl and add Mn2-arm C5 chelate (0.500 g, 0.956 mm ol; obtained according to Example 2(v)) was added, followed by EDCI-HCl (0.445 g , 2.32 mmol) and HOBt hydrate (0.045 g, 0.333 mmol) were added. Add 1.0M HCl or 1.0M HCl as needed while stirring at ambient temperature for 20 hours. NaOH was added to maintain the pH at 6. Diethanolamine (0.207 g, 1. 97 mmol) and EDCI-HCl (0.432 g, 2.25 mmol) were added, The pH was maintained at 6 with stirring at ambient temperature for 8 hours. Diethanolamine (0.207 g , 1.97 mmol) and EDCI-HCl (0.448 g, 2.34 mmol) were added. The reaction solution was concentrated in vacuo and stirred at ambient temperature for 15.5 hours while maintaining the pH at 6. The crude product was dried and purified by C 18 Purify with silica gel (100% water to 30% AcN in water) to obtain 0 110 g (16%) of the desired product was obtained as a pale yellow solid (ESI: m / z=708 (M+H + )).

[0184] Example 6: Synthesis of Mn chelate 10

[0185] [ka] In a 25 mL two-neck flask equipped with a magnetic stir bar, add 3-aminopropane-1,2-diaminetetraacetate. The mixture was charged with ethanol (0.190 g, 2.03 mmol) and water (10.4 mL). The pH of the resulting solution was adjusted to 7 with 1.0 M HCl, and the Mn2-arm C5 chelate (0.603 g, 0.996 mmol; obtained according to Example 2(v) was added, followed by EDCI-H Cl (0.473 g, 2.47 mmol) and HOBt hydrate (0.063 g, 0.4 66 mmol) was added as needed with stirring at ambient temperature for 7.5 hours. The pH was maintained at 6 by addition of HCl or 1.0 M NaOH. -1,2-diol (0.095 g, 1.04 mmol) and EDCI-HCl (0. 453 g, 2.36 mmol) was added and the pH was adjusted to 6 with stirring at ambient temperature for 15.5 hours. The reaction solution was concentrated to dryness in vacuo and the crude product was 18 Silica gel (100% water ~ 20% AcN in water) to give 0.280 g (41%) of the desired product as a pale yellow solid. (ESI: m / z=680 (M+H + )).

[0186] Example 7: Synthesis of Mn chelate 11

[0187] [ka] In a 100 mL three-neck round-bottom flask equipped with a magnetic stir bar, add Tris base (0.632 g, The resulting solution was adjusted to pH 1.0. Adjust the concentration to 7 with M HCl and dilute the Mn2-arm C5 chelate (1.500 g, 2.49 mmol) ;obtained according to Example 2(v)) was added, followed by EDCI-HCl (1.141 g, 5 0.95 mmol) and HOBt hydrate (0.160 g, 1.04 mmol) were added. Add 1.0 M HCl or 1.0 M HCl as needed while stirring at ambient temperature for 7.5 hours. The pH was maintained at 6 by adding aOH. Tris (0.636 g, 5.25 mmol) and and EDCI-HCl (1.177 g, 6.14 mmol) were added and incubated at ambient temperature for 17 hours. The pH was maintained at 6 with stirring for 1 hour. Tris (0.624 g, 5.15 mmol) and EDCI-HCl (1.133 g, 5.91 mmol) was added and stirred at ambient temperature for 23 h. The pH was maintained at 6 with stirring. The reaction solution was concentrated to dryness in vacuo and the crude product was 18 Siri The mixture was purified by gel chromatography (100% water to 20% AcN in water) to obtain 0.247 g (13%) of the desired product. The product was obtained as a pale yellow solid (ESI: m / z=740 (M+H + )).

[0188] Example 8: Synthesis of Mn chelate 5a Example 8(i): Synthesis of protected Mn2-arm C4 chelates

[0189] [ka] In a 250 mL round-bottom flask equipped with a mechanical stirrer, add the two-arm cyclic chelate (19.8 5 g, 90.1 mmol; obtained according to Example 2(iii)), dimethyl maleate (5 1.94g, 360.4mmol), Montmorillinite K10(36. 0 g), and MeOH (36 mL). The resulting suspension was stirred at ambient temperature for 26 h. The insoluble material was removed by filtration and the clear orange filtrate was concentrated to dryness. Dissolve in EtOAc (200 mL) and extract with water (200 mL). Separate the layers and remove the aqueous layer. Concentration to dryness gave 39.35 g (86%) as an orange solid (ESI: m / z=509 (M+H + ) which was used without further purification.

[0190] Example 8(ii): Synthesis of Mn2-arm C4 chelate

[0191] [ka] In a 1 L round bottom flask equipped with a magnetic stir bar, add the protected Mn2 arm C4 chelate ( 39.35g, 77.2mmol), sodium hydroxide (24.71g, 617mmol) ) and water (500 mL) were charged. The resulting solution was stirred at 45° C. for 4 hours. The pH was adjusted to Adjust the pH to 7 with concentrated HCl and add MnCl4·4H2O (16.8 g, 84.9 mmol). The pH was maintained at 7 with stirring at 90° C. for 2.5 hours before being cooled to ambient temperature. The pH was adjusted to 10.1 with 6.0 M NaOH and the resulting precipitate was stirred at 3000 rcf for 20 min. The supernatant was collected and evaporated to dryness in vacuo. The residue was diluted with MeOH (72 mL) at 40° C. for 1.5 hours. The insoluble white solid was triturated at 3000 rcf. The supernatant was concentrated to dryness in vacuo to give an off-white solid, which was then removed by centrifugation for 30 minutes. C 18 Purify on silica gel (3% AcN in water) to give 25.8 g (66%) of the desired product. The product was obtained as an off-white solid (ESI: m / z=506 (M+H + )).

[0192] Example 8(iii): Synthesis of Mn chelate 5a

[0193] [ka] In a two-neck 50 round-bottom flask equipped with a magnetic stir bar, add 100 mL of Mn2-arm C4 chelate (0.66 7 g, 1.32 mmol) and water (13.0 mL). 5 g, 2.79 mmol) was added and the pH was adjusted to 7 with 1.0 M HCl. -HCl (0.599 g, 3.12 mmol) and HOBt hydrate (0.036 g, 0 0.266 mmol) was added and stirred at ambient temperature for 7.5 hours while adding 1.0 M The pH was maintained at 6 by addition of HCl or 1.0 M NaOH. A second aliquot (0.610 g, 3.18 mmol) was added and the mixture was stirred at 16.5 °C for 2 h at ambient temperature. The pH was maintained at 6 with stirring for 1 h. A third aliquot of EDCI-HCl (0.61 0 g, 3.18 mmol) was added and the pH was maintained at 6 with stirring at ambient temperature for 72 hours. The reaction solution was concentrated to dryness in vacuum, and the crude product was 18 Silica gel (100% water to 3 in water) 0% AcN) to give 0.350 g (31%) of the desired product as a pale yellow solid. (ESI: m / z = 832 (M+H + )).

[0194] Example 9: Synthesis of Mn chelate 7a

[0195] [ka] In a 100 mL three-neck round bottom flask equipped with a magnetic stir bar, add 5-amino-N,N'-bis(2-(2-methylphenyl)-2-propanediol). (2,3-dihydroxypropyl) was charged.

[0196] Isophthalamide hydrochloride (1.516 g, 4.17 mmol) and water (20 mL). The pH of the resulting solution was adjusted to 8 with 1.0 M NaOH and the Mn2-arm C4 chelate (1 0.000 g, 1.98 mmol; obtained according to Example 8(ii)) was added, followed by ED CI-HCl (0.901 g, 4.70 mmol) was added. The mixture was stirred at ambient temperature for 6.5 hours. Adjust the pH to 1.0M with stirring by adding 1.0M HCl or 1.0M NaOH as needed. The temperature was maintained at 6. A second aliquot of EDCI-HCl (0.895 g, 4.67 mmol ) was added and the pH was maintained at 6 with stirring at ambient temperature for 16.5 hours. A third aliquot of 1.0 ml (0.417 g, 2.18 mmol) was added and incubated at ambient temperature for 8 h. The pH was maintained at 6 with stirring. A fourth aliquot of EDCI-HCl (0.536 g , 2.80 mmol) was added and the pH was maintained at 6 with stirring at ambient temperature for 17 hours. The cloudy reaction mixture was vacuum filtered to remove solids. The clear yellow filtrate was concentrated to dryness to give the crude product. The product is C 18 Purify with silica gel (100% water to 20% AcN in water) to obtain 0.494 g The desired product (22%) was obtained as a pale yellow solid (ESI: m / z=1124 (M + ) ).

[0197] Example 10: Synthesis of Mn chelate 10a

[0198] [ka] In a two-necked 50 mL round-bottom flask equipped with a magnetic stir bar, add 100 mL of Mn2-arm C4 chelate (0 0.667 g, 1.32 mmol; obtained according to Example 8(ii)) and water (13.0 m 3-amino-1,2-propanediol (0.253 g, 2.77 mm ol) was added and the pH was adjusted to 7 with 1.0 M HCl. 99 g, 3.12 mmol) and HOBt hydrate (0.036 g, 0.266 mmol) ) was added and stirred at ambient temperature for 7 h with 1.0 M HCl or 1.0 M NaOH was added to maintain the pH at 6. A second aliquot of EDCI-HCl ( 0.610 g, 3.18 mmol) was added and the pH was adjusted to 0.05 with stirring at ambient temperature for 17.5 hours. The pH was maintained at 6. A third aliquot of EDCI-HCl (0.610 g, 3.18 mmol) was added. l) was added and the pH was maintained at 6 with stirring at ambient temperature for 70 hours. Concentrate to dryness and obtain the crude product 18Purify with silica gel (100% water - 30% AcN in water). The desired product was obtained as a pale yellow solid (ESI: m / z = 0.160 g, 19%). 652(M+H + )).

[0199] Example 11: Synthesis of prior art Mn chelates Example 11(i): Synthesis of protected MnO arm chelates

[0200] [ka] In a 100 mL three-neck round bottom flask equipped with a magnetic stir bar and reflux condenser, Cyclic 2-arm chelate (4.51 g, 8.53 mmol; obtained according to Example 2(ii) ) and concentrated sulfuric acid (18.0 mL) and heated at 100° C. for 18 hours. The mixture was cooled to room temperature and placed in an ice bath before the pH was adjusted to 9.9 with 50% aqueous NaOH. The resulting suspension was transferred to a 250 mL three-neck round-bottom flask and diluted with anhydrous potassium carbonate (11.78 g , 85.2 mmol) was added, followed by AcN (25 mL) and t-butyl bromoacetate. Salt (6.64 g, 34.0 mmol) was added and the reaction was heated at 70° C. for 3 hours. It was cooled to ambient temperature and the solids were removed by vacuum filtration. The filtrate was washed with AcN (3×50 mL). The organic layer was concentrated to dryness to give a dark brown oily substance, which was then 18 Silica gel (100 1.28 g (33%) of the desired product was obtained as an off-white solid. Obtained as a solid. 1 H NMR(400MHz, CD3CN, δ)7.67(1H,m) , 7.12(2H,m), 5.14(2H,bs), 3.95(4H,m), 3.44( 4H,m), 3.28(6H,m), 3.16(2H,m), 2.78(3H,s), 1 .42(18H,s).

[0201] Example 11(ii): Synthesis of deprotected MnO arm chelate

[0202] [ka] In a 100 mL three-neck round bottom flask equipped with a magnetic stir bar and reflux condenser, MnO arm chelate (1.28 g, 2.85 mmol), AcN (8.4 mL) and THF (21 mL) was added. 88% aqueous formic acid (29.1 mL, 556 mmol) was added. A second aliquot of 88% aqueous formic acid was added and the resulting solution was heated at 65° C. for 4 hours. (29.1 mL, 556 mmol) was added and heating was continued for a further 9 h. The solvent was removed in vacuo Removal with rt left a yellow oil which was used without further purification. 1 HN MR(400MHz, CD3OD, δ)7.74(1H,m), 7.20(2H,m), 4.07(4H,m), 3.65(4H,m), 2.91(3H,s), 2.99(4H ,m), 1.92(4H,m).

[0203] Example 11(iii): Synthesis of prior art Mn chelates

[0204] [ka] In a 250 mL round bottom flask equipped with a magnetic stir bar, add the deprotected MnO arm chelate. (0.959 g, 2.85 mmol) and manganese(II) chloride tetrahydrate (1.11 The pH was adjusted to 1.0 M NaOH and 1.0 M NaOH as needed. The pH was adjusted to 7.4 with 0.0 M HCl and the resulting solution was stirred at ambient temperature for 15.5 hours. The pH was adjusted to 10 with saturated aqueous sodium carbonate, and the resulting off-white precipitate was filtered under vacuum. The filtrate was concentrated to dryness in vacuo and 18 Silica gel (100% water to 10% in water) % AcN) to give 0.511 g (46% over two steps) of the desired product as a pale yellow solid. (ESI: m / z = 390 (M + )).

[0205] Example 12: In vivo in rats 54 Mn biodistribution study For biodistribution studies 54 The Mn-labeled chelate was prepared using the following method. In a 3 mL glass vial equipped with a stir bar, add 1 mg of each manganese-containing chelate. and 1.0 M ammonium formate, pH=4 (0.5 mL) (for the Mn chelate of the prior art) Next, 1.0M HCl was added. 54 MnCl2 (approximately 500μ Ci) was added and the resulting solution was heated at 40° C. for 16 h. The resulting solution was purified by preparative HPLC. The radioactive fraction was collected and purified by HCl under vacuum to remove unchelated Mn. The radioactive residue was dissolved in water containing non-radioactive Mn chelate (0.310M). The radioactivity of about 30 μCi was dissolved in 0.620 mmol Mn / It was formulated in a kg dose.

[0206] The experimental protocol complies with the Guide for the Care and Use of Laboratory Animals and is in accordance with the General The IACUC at Electric Global Research (Niskayuna, NY) Female Sprague-Dawley rats (130–150 g; Charles River R Laboratories; Massachusetts; USA) were used as standard commercial food and The mice were housed in standard cages with free access to water and water in a temperature- and humidity-controlled room. They were maintained on an alternating 12-hour light / dark cycle. 54 Prior to injection of the Mn-labeled chelate, rats were Patients were administered inhaled 3% isoflurane (Piramal, NDC66794-013-25; EZ- Anesthesia was administered using an EZ700 isoflurane vaporizer (S / N107) An alcohol wipe was prepared at the injection site, and a short-term 27 Ga catheter (Surfl o SROX 2419 V) was placed into the tail vein. 30 μCi (0.74 MBq) of chelate 54 The Mn-labeled chelate was 0.620 mmol of non-radioactive Mn chelate / kg was administered in a 2 mL / kg injection volume, and 1 The first urine void was collected after injection at a rate of 100 mL / min. The animals were housed individually in wire-bottom cages lined with filter paper until the rats The mice were housed together in standard long-term cages. Seven days after injection, the animals were sacrificed by CO2 immersion. The organs and tissues of interest were removed and counted in a Wizard 2480 gamma counter ( Radioactivity was assessed using a 100-milligram plate (ErkinElmer, Beaconsfield, UK). did.

[0207] Naibrat (Charles River Laboratories; Massachusetts) -set; United States) in a single dose of 0.620 mmol / kg (approximately 30 μCi, 0.740 One group of animals was then administered 1000 mg of the test item (1000 mg / kg, ... Osmolarity-matched saline (for injection, concentrated NaCl:AP mixed with sterile water for injection) P Pharmaceuticals Part Number NDC63323-187-30, Lot Part number 6008656: Hospira part number NDC0409-7990-09, lot No. 49-396-DKas) was administered as a negative control (Table 1). and tissues were removed and the residual radioactivity 7 days after a single dose (i.e., 54 Mn organ retention) The following was evaluated:

[0208] Table 1. In rats 54 Study design for Mn biodistribution study. Test items: Prior art M Mn chelate; Mn chelate 3 and Mn chelate 4. Residual radioactivity (%ID) was measured by single i.v. The subjects were evaluated 7 days after oral administration.

[0209] [Table 1] The purpose of this study is to 54 Mn(II)-based chelates labeled with Mn (radioisotope) The objective of this study was to evaluate the tissue distribution in naive rats 7 days after a single injection of Radioactivity (e.g., %ID) was measured in relevant collected tissues (Table 2). The Mn(II)-based chelates were physiologically active in almost all organs and tissues collected. Within the range of variation in manganese levels 54 Mn retention levels were observed, with trace amounts present in excretory organs. In the liver and kidney 54 The detection of Mn indicates that these organs are the major This was expected for all compounds evaluated, as it is part of the excretion pathway. Chelates are 54 Decreased distribution to heart and brain compared to literature data using MnCl2 In fact, Mn chelate 3 and Mn chelate 4 were detected in the brain.54 Mn Low levels of Mn(II) (e.g., within the range of endogenous levels) suggest that the brain is not susceptible to Mn(II) toxicity. Surprisingly, Mn chelates 3 and 4 are the most abundant target organs in the body. In the tibia / fibula and femur 54 Low levels of Mn also contribute to bone loss due to the free metal ions ( For example, considering that the Mn(II) deposit acts as a reservoir for Mn(II), the Mn(II) in the prior art The results show improved in vivo stability of this class of compounds compared to the three Mn(I I) The biodistribution profile of the chelates shows that the in vivo stability of the paramagnetic complex depends on the chelate moiety. This is a property that can be tuned by structural design, and Mn-chelate 3 and Mn-chelate 4 have been the first to be developed. 4 shows that it exhibits improved stability compared to the Mn chelates of the art.

[0210] Table 2: %ID ± standard deviation of collected tissues. Retained radioactivity was approximately 30 μCi. 54 Mn labeling Seven days after administration of a single dose of 0.62 mmol non-radioactive Mn chelate / kg containing was measured.

[0211] [Table 2] Example 13: Aqueous solubility of Mn(II)-based chelates The solubility of Mn(II)-based chelates was determined by solubility in a given amount of solvent (Millipore BioCells Purified Millipore water (18.2 MΩ) from a benchtop facility The measured amount of the solution was determined by dissolving Mn(II) chelate (purity: about 99%). The solutions were visually inspected for homogeneity and filtered through a 0.45 um PTFE membrane if necessary. The samples were filtered through a filter. The evaluation was carried out at 25°C. The final sample concentrations were determined by ICP-MS (Spec tro Arcos FHS12, S / N10003910 or S / N1200612 This was confirmed by determination of the final Mn(II) concentration by HPLC.

[0212] The size of the paramagnetic complex determines its aqueous solubility and therefore its distribution into the extracellular space and removal from the body. Sufficient aqueous solubility can facilitate administration of the contrast agent to the patient. It is also necessary to keep the injection volume low in order to prevent the A commercially available Gd(III) contrast agent is mixed at a concentration of 0.5M. The solubility of the compound increases with increasing molecular size, independent of the observed increase in molecular size for some compounds. The solubility of these compounds was confirmed to be within the typical solubility range (>0.5M) (Table 3).

[0213] Table 3: MW and solubility ranges of exemplary Mn(II)-based chelates included in the present invention. The solution was evaluated at 25°C.

[0214] [Table 3] Example 14: In vitro proton relaxivity and nuclear magnetic relaxation of Mn(II)-based chelates Sum Dispersion (NMRD) Profile Both the longitudinal and transverse relaxation times were measured using human serum (Bioreclamation IVT, The Mn(II) system was measured in a 100-mM 2000-mL 1 ... Mn(II)-containing 100-mL Mn(II)-containing 100-mL Mn(II)-containing 100-mL Mn(II)-containing The relaxivity was evaluated using an inversion recovery pulse sequence at 60 M. Minispec Mq benchtop NMR relaxometer operating at 1.4 Hz (1.4 T) A 300-millimeter meter (Bruker Instruments, Rheinstetten, Germany) was used. The experiments were carried out at 40 °C and with concentrations ranging from 5 to 0 mM Mn(II). The degree of relaxation (e.g., r1 and r2, respectively) is The reciprocal of the time was measured using an ICP-MS (Spectro Arcos FHS12, S / N 100 The manganese concentration determined by the The dependence of T1 on the applied B0 (i.e. magnetic field) was calculated by plotting teeth, 1 The H nuclear magnetic relaxation dispersion (NMRD) profiles were obtained. telar SMARTracer Fast Field Cycling Relaxation Time Measurement It is suitable for fixed field measurements (0.01 to 10 MHz) and variable field measurements (20 to 80 MHz). , Bruker W controlled by a SMARTracer PC-NMR console The P80 NMR electromagnet is used to measure an extended range of Larmor frequencies (0.01 to up to 80MHz 1 H NMRD profiles were recorded. The temperature was VTC91 The temperature was monitored by a temperature controller and maintained by gas flow. The temperature was measured by the Pt resistor temperature. The high field relaxivity was determined by a previous calibration with the Bruker AV A total of 2 NMR profiles were obtained using a ANCE NMR spectrometer at 400 MHz. 5 data points are compared for the prior art Mn-chelates, Mn-chelate 4 and Mn-chelate 3. For each temperature, pH 6.9, and manganese concentration in the sample was 6.99, 6.78, and 4. The concentration of Mn(II) in all samples was recorded at 0.45 mM, respectively. The relaxivity was verified by BMS measurements. The relaxivity was measured for the Mn(II) complex solution at each magnetic field strength. The relaxation rate of the medium (distilled water) was subtracted from the relaxation rate of the sham strain, and the difference was calculated as a mangan It is calculated by dividing by the concentration of

[0215] Linear fits of 1 / T1 and 1 / T2 as a function of Mn concentration (for all compounds tested) For samples, R2 > 0.99) is the r1 or r2 value reported in Table 4 for human serum. was generated.

[0216] Table 4: Human blood at 60 MHz and 40° C. for exemplary Mn(II)-based chelates Relaxivities r1 and r2 in the supernatant.

[0217] [Table 4] Relaxivity measurements are feasible for all Mn(II)-based chelates, including commercially available MRI contrast agents. Within the range of standard relaxivities (i.e., r1 and r2) of -1 s -1 Of particular interest is the fact that T1 (or positive) was observed in vivo after intravenous administration. The r1 of Mn(II)-based chelates, which represents the ability of the chelate to generate contrast (i.e. On the other hand, the r2 (i.e. transverse relaxivity) value is the T2 (or transverse relaxivity) value after intravenous administration. represents the ability of Mn(II)-based chelates to generate negative contrast.

[0218] 1 1 H NMRD profiles for the prior art Mn chelates and Mn chelate 4 Both Mn(II)-based chelates evaluated showed longitudinal The relaxivity is lower than that of the Mn(II) aqua ion, and there is only one in the profile around 1 MHz. A feasible 1 The H NMR profile of Mn chelate 4 is shown. The MRD profile (Fig. 3) shows that the small This is consistent with the small r1 hump observed for Mn(II)-based chelates at clinically relevant magnetic field strengths. The improved efficiency may be advantageous for future clinical imaging applications. This is due to the slight decrease in tumbling rate associated with the larger molecular size of the compounds.

[0219] Example 15: Dissociation rate of Mn(II)-based chelates The kinetic inactivity is due to the slow dissociation rate of the paramagnetic complex at physiological pH and the Due to the potential for hydrolysis of metal ions at concentrations and near-physiological pH values ​​that are , evaluated at a slightly acidic pH.

[0220] Zinc 2+ exchange The dissociation rate of the Mn(II)-based chelate of the present invention (at a concentration of 1 mM) was measured using the longitudinal relaxation time (i.e. Record the time-dependent changes in T1 2+ The evaluation was carried out by transmetalation. , and different concentrations of competing metal ions (5, 10, 20, 40 equivalents of Zn 2+ ) at 25°C and different pH values ​​(pH: 5.1: 5.4: 5.7). The dissociation rate of Mn chelate 4 (at a concentration of 1 mM) was 25 °C, pH 5.1 and 5.7, 5 equivalents of Zn 2+ Both evaluations were performed in the presence of The reaction mixture was buffered with 0.15 M NaCl and 50 mM N-methylpiperazine. The change in longitudinal relaxation time was measured for the prior art Mn chelates. The Zn chelate 4 was monitored at 1 MHz and the Mn chelate 4 at 0.01 MHz. 2+Release of Mn induced by 2+ Ion release was evaluated in all experimental conditions. This results in a decrease in the relaxation time of the Mn(II) chelate. The obtained frequencies for this series of experiments are The observed relaxivity of Mn(II) aqua ion and Mn(II)-based chelates (e.g., The two were selected based on the difference in relaxivity between the Mn chelate and the Mn chelate 4) of the conventional technique. The frequencies were determined so that there was sufficient discrimination between the chemical species of the prior art Mn chelate, M As shown in FIG. 1 for n-chelate 4 and MnCl2 1 H NMRD Profile The models were selected based on their

[0221] Cu 2+ exchange Prior art Mn-chelates, Mn-chelate 4 and Mn-chelate 3 at a concentration of 0.2 mM The dissociation rate of was measured at 25°C and different pH values ​​(pH: 5.0: 5.2: 5.4) with excess competitive The metal ions (10 and 40 equivalents of Cu 2+ ) in the presence of Cu to record time-dependent changes 2+ All evaluations were performed using transmetallization. The reaction mixture contained 0.15M NaCl:50mM NMP. λ for the acquisition of s spectra is determined using Mn(II)-based chelates (e.g., Mn(II) chelates of the prior art) chelate, Mn chelate 3 and Mn chelate 4) and the newly formed Cu 2+ -complex was chosen based on the observed absorbance difference between the two species to provide the best discrimination between the two species. UV-Vis spectra were obtained using a Perkin-Elmer Lambda 1 The results were obtained using a spectrophotometer at λ = 300 nm. 2+Mn(I) induced by I) Ion exchange was λ for all Mn(II)-based chelates under all experimental conditions. This resulted in an increase in absorbance observed at 300 nm. 2+ -Complex form By composition.

[0222] Results of transmetallation experiments Zinc 2+ and Cu 2+ Transmetallation of Mn(II)-based chelates is a kinetic inactivation The use of an excess of exchangeable metal ions was investigated to demonstrate the activity of the prior art Mn Using chelates (e.g., different pH: different Zn 2+ or Cu 2+ (at concentration) In all transmetallation experiments, the reaction was not induced by competing metal ions. Change in relaxation rate T1 (Zn 2+ exchange; Figure 4) or fluctuations in UV-Vis absorbance (Cu 2+ exchange; Fig. 5), but is a "single-phase" process that is better described by a single exponential function. It was clear that the reaction rate of the prior art Mn chelates was Mn(I I) The exchange reaction was governed by a pseudo-first-order equation (1) that was directly proportional to the total concentration of the chelates in the system. obs The dissociation rate described by [MnL] tot is the total amount of Mn(II) chelates. The concentration was calculated according to equation (1), where t is the observation time.

[0223]

number

[0224] To confirm the biphasic nature of the dissociation rate curves of Mn-chelate 3 and Mn-chelate 4 , Zn 2+ The transmetallation reaction by Mn-chelate 4 was evaluated. The time-dependence curves of the oxidative stress (i.e., T1) were recorded at pH 5.1 and 5.7 (Figure 8). These curves indicate a biphasic behavior of the rate curves and therefore a biphasic dissociation process of Mn chelate 4. This confirmed the behavior of

[0225] Mn chelate 3 and Mn chelate 4 are governed by the sum of two independent exponential functions. These biphasic rate curves can be mathematically expressed as follows: where A is the observed absorbance: b, A1, and A2 are is a constant specific to the biphasic dissociation process of Mn(II) chelates: k obs1 and k obs2 is the rate constant describing the biphasic dissociation and t is the observation time.

[0226]

number

[0227] Table 5: Cu 2+ Monoexponential equation for transmetallation (for prior art Mn chelates) or was calculated by a biexponential equation (for Mn-chelate 3 and Mn-chelate 4), The calculated rate constant k obs1 and k obs2 .

[0228] [Table 5] Speed ​​curve and preliminary k obs From the qualitative comparison of Mn chelate 3 and Mn chelate 4, The mechanism is biexponential and slower than that of the prior art Mn chelates. The kinetic inactivity of these Mn(II) chelates was To quantitatively compare the evolution of UV-Vis absorbance at 300 nm, a direct comparison of the 2+ The exchange reaction was recorded. A direct comparison of the UV-Vis absorbance of the Mn(II) complexes was performed. Cu in Mn(II)-based chelates during transmetallation reactions correlated with kinetic inactivity. 2 + This allows the quantification of the conversion of the system to chelate. The "conversion" was calculated according to equation (3). Medium, A tis the absorbance at time t (or the end of the reaction), and A0 is the absorbance at time zero (or the is the absorbance at the start of eq is the absorbance at equilibrium.

[0229]

number

[0230] Using the same mathematical method, Zn 2+ It is caused by a transmetallation reaction with Conversion was also compared for the prior art Mn-chelate and Mn-chelate 4 (Figure 11). This evaluation demonstrated the superior kinetic inactivation of Mn-chelate 4 compared to prior art Mn-chelates. It clearly indicates gender.

[0231] Thus, Mn-chelate 3 and Mn-chelate 4 have a higher Cu content than the prior art Mn-chelates. 2+ and Zn 2+ Surprisingly, under the same experimental conditions, MnL (i.e., Mn(II) complex) and Zn(II) complex showed different, slower dissociation mechanisms in the transmetalation. 2+ or Cu 2+The improved kinetic inactivity was demonstrated by directly comparing the conversion of the three compounds that occurred during the transmetallation reaction between Mn(II) and Mn(II). All dissociation rate results showed a clear improvement in the overall kinetic inactivity of Mn-chelate 3 and Mn-chelate 4 compared to the prior art Mn-chelate as the reference. In fact, Mn-chelate 4 became the most kinetically inactive compound investigated in all experimental conditions. It can be hypothesized that the presence of a side chain with -OH group successfully encapsulates the smaller Mn(II) metal and protects Mn from dissociation, thus contributing to the increased kinetic inactivity of this class of Mn(II)-based chelates. The present invention includes the following aspects. <1> Compounds of Formula I [ka] or a salt or solvate thereof, (Wherein, each R 1 are independently 1~20 Hydroxyalkyl, C 1~6 Alkyl, halo and -C(=O)-NH-C 1~6 C, optionally substituted with one or more substituents selected from hydroxyalkyl 3~6 aryl, or carbohydrate moiety; Each R 2 are independently 1~20 Hydroxyalkyl, C 1~6 selected from the group including alkyl or hydrogen; R 3 is C 1~3 Alkyl or m is an integer of 2 to 5 -(CH 2 ) m -C(=O)-NR 5 R 6 and R 5 and R 6 is R 1 and R 2 as defined herein; R 4 is hydroxy, C 1~6 Alkyl and C 1~6 represents 0 to 3 substituents selected from the group consisting of hydroxyalkyl; and each n is an integer from 0 to 4); The compound of formula I contains at least two hydroxy groups. <2> Each R 1 But, C 1~12 is hydroxyalkyl, <1> The compound according to claim 1, <3> Each R 1 C 3~6 is hydroxyalkyl, <1> or <2> The compound according to claim 1, <4> Each R 1 C 6 is hydroxyalkyl, <1> ~ <3> 2. The compound according to claim 1 , <5> Each R 1 But independently,

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

Claims

1. Compounds of Formula I [Formula 1] or a salt thereof, (In the formula, Each R 1 are, independently, [Case 2] where in each case the asterisk indicates the point of attachment to the remainder of the compound of formula I; and one or more -C(=O)-NH-CH 2 -C(OH)-CH 2 -C(OH)-substituted phenyl, optionally substituted with one or more halo; Each R 2 are independently 1~20 Hydroxyalkyl, C 1~6 selected from the group consisting of alkyl, aryl, aryloxy ... R 3 is methyl; R 4 is hydroxy, C 1~6 Alkyl, and C 1~6 represents 0 to 3 substituents selected from the group consisting of hydroxyalkyl; and each n is an integer from 0 to 4; A compound or a salt thereof.

2. 2. The compound or salt thereof of claim 1, wherein said halo is iodo.

3. Each R 1 The compound or salt thereof according to claim 1 or 2, wherein

4. Each R 2 C 1~3 4. The compound or salt thereof according to claim 1, wherein the aryl group is alkyl.

5. Each R 2 The compound or salt thereof according to claim 4, wherein is methyl.

6. Each R 2The compound or salt thereof according to any one of claims 1 to 3, wherein is hydrogen.

7. Each R 2 C 1~20 4. The compound or salt thereof according to any one of claims 1 to 3, which is hydroxyalkyl.

8. Each R 2 But, C 1~6 8. The compound or salt thereof according to claim 7, which is hydroxyalkyl.

9. Each R 2 The compound or salt thereof according to any one of claims 1 to 8, wherein

10. 10. The compound according to any one of claims 1 to 9, wherein each n is an integer from 1 to 3, or a salt thereof.

11. 11. The compound of claim 10, or a salt thereof, wherein each n is 1.

12. 11. The compound of claim 10, or a salt thereof, wherein each n is 2.

13. 11. The compound of claim 10, or a salt thereof, wherein each n is 3.

14. R 4 14. The compound according to any one of claims 1 to 13, or a salt thereof, wherein represents 0 substituents.

15. R 4 14. A compound according to any one of claims 1 to 13, or a salt thereof, wherein represents 1 or 2 hydroxy groups.

16. R 4 16. The compound according to claim 15, or a salt thereof, wherein represents two hydroxy groups at the meta positions of the pyridyl ring.

17. 17. A compound or salt thereof according to any one of claims 1 to 16, comprising at least four hydroxy groups.

18. 18. The compound according to claim 17, or a salt thereof, comprising 4 to 15 hydroxy groups.

19. 19. The compound of claim 18 or a salt thereof, comprising 5 to 10 hydroxy groups.

20. The Mn is 52 Mn and 54 20. The compound or salt thereof according to any one of claims 1 to 19, which is isotope enriched in Mn selected from the group including Mn.

21. 15. A compound according to any one of claims 1, 3, 6, 9, 12 and 14, or a salt thereof.

22. R 1 but, [chemical 2-1] 13. The compound according to any one of claims 1, 3, 6, 9, and 12, or a salt thereof.

23. 23. A diastereomerically pure compound of formula I according to any one of claims 1 to 22, or a salt thereof.

24. 24. A process for the preparation of a compound of formula I or a salt thereof according to any one of claims 1 to 23, comprising: (i) activating the carboxylate group of the compound of formula II with a peptide reagent; [C30] next, (ii) reacting the activated compound of formula II with a substituent -NR 1 R 2 to arrive at said compound of formula I or a salt thereof. Including, In the formula, R 1 and R 2 is as defined in claim 1 and X 1 is methyl.

25. 25. The method of claim 24, wherein the peptide reagent is selected from 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) or hydroxybenzotriazole (HOBT).

26. Compound of Formula III [C31] (In the formula, X 1 25. A process for the preparation of a compound of formula II as claimed in claim 24 comprising the alkylation of

27. 24. A pharmaceutical composition comprising a compound of formula I, or a salt thereof, as defined in any one of claims 1 to 23, together with a biocompatible carrier in a form suitable for mammalian administration.

28. 28. The pharmaceutical composition of claim 27, further comprising one or more pharma- ceutically acceptable excipients.

29. 29. The pharmaceutical composition of claim 28, wherein the pharma- ceutically acceptable excipient is selected from buffers, stabilizers, antioxidants, osmolality regulators, pH adjusters, excess neutralizers, and physiologically tolerable weak complexes of ions.

30. (i) administering to a subject the compound of formula I or a salt thereof according to any one of claims 1 to 23, or the pharmaceutical composition according to any one of claims 27 to 29; (ii) detecting a magnetic resonance (MR) signal from the subject or a portion of the subject in which the compound or salt thereof is distributed; (iii) generating an MR image and / or an MR spectrum from the detected signals. A pharmaceutical composition for use in the method comprising:

31. 30. Use of a compound according to any one of claims 1 to 23, or a salt thereof, in the manufacture of a pharmaceutical composition according to any one of claims 27 to 29.

Citation Information

Patent Citations

  • Bicyclic polyamino acid metal conjugates, their preparation and use in medical imaging

    JP2003501430A

  • Compounds Containing Short Aminoalcohol Chains and Metal Complexes for Medical Imaging

    JP2009513574A

  • Manganese chelate and its use as a contrast agent in magnetic resonance imaging (MRI)

    JP2013514329A

  • JPP7048591B

  • Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI

    US5334371A